Earnings Call · Q1 FY2023·2023-05-08

Q1 23EPS +10.00%·Rev n/aQ4 22EPS +23.17%·Rev n/aQ3 22EPS -2.35%·Rev n/aQ2 22EPS +2.38%·Rev n/a⚠ consensus missing

Revolution Medicines, Inc. RVMD

Erin Graves — Senior Director of Corporate Communications and Investor Relations

Mark Goldsmith — Chairman and Chief Executive Officer

Steve Kelsey — President of R&D

Jack Anders — Chief Financial Officer

+0.4%1d on move date+0.4% vs SPY3d+3.2%5d+6.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RVMD calls or request research access.

More RVMD calls Browse calls Request research access